MPV as a Predictor for ACS in Patients With MASLD
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSohag University
About this trial
The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Sohag University Hospital.
Eligibility criteria
Qualifiers
Adult patients aged ≥18 years.
Confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) based on clinical, laboratory, and imaging criteria).
Patients diagnosed with acute coronary syndrome (unstable angina, NSTEMI, or STEMI) for Group I.
MASLD patients without clinical or electrocardiographic evidence of acute coronary syndrome for Group II.
Disqualifiers
Patients with chronic liver diseases other than MASLD (e.g., viral hepatitis, autoimmune hepatitis, alcoholic liver disease).
Patients with known hematological disorders affecting platelet count or function.
Patients receiving antiplatelet or anticoagulant therapy prior to blood sampling.
Patients with active infection, inflammatory diseases, or malignancy.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov